The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of two GLP-1 drugmakers were on full display this week. Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly’s results, sending shares higher on Wednesday, they punished Novo…
Novo Nordisk’s quarterly beat and guidance increase did little to resolve Wall Street’s biggest concern: whether the Ozempic maker has a convincing path back to sustainable growth as competition from Eli Lilly intensifies. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, obesity drug sales were broadly in line with expectations,…
The jobs market steps into the spotlight this week, while second-quarter earnings season continues apace. Here’s a closer look at what to expect in the coming days. We’ll start with the Club holdings set to report, before touching on the labor-market updates and their implications for Federal Reserve policy. 1. Earnings : The action kicks…
Wall Street got back to its winning ways last week after navigating a hawkish Federal Reserve meeting, volatile swings in chip stocks, and a critical round of Big Tech earnings. The Dow Jones Industrial Average rose 1% for the week, snapping a three-week losing streak. The S & P 500 gained 1% last week, while…
A pharmacy at a Costco store in Teterboro, New Jersey, US, on Wednesday, Feb. 28, 2024. Bloomberg | Bloomberg | Getty Images As more Americans use GLP-1 weight-loss drugs to shrink their waistlines, retail giants are betting on a bottom-line bump tied to a shift in the way the drugs are priced and purchased. Employers…
Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in so-called MACE, defined as cardiovascular death, non-fatal heart attack…
Novo Nordisk shareholders are suing the drugmaker over its experimental obesity treatment CagriSema, alleging the company misled investors about a key clinical trial before releasing disappointing results that wiped billions of dollars off its market value. A federal judge on Tuesday allowed parts of that lawsuit to move forward, finding that investors had plausibly alleged…
It was a tough week for stocks, as investors navigated everything from escalating tensions in the Middle East to key tech earnings reports to healthcare developments. Logging their second straight weekly losses, the S & P 500 slipped 0.6%, while the tech-heavy Nasdaq fell 2.1%. Here’s a closer look at what drove the trading action….
A FedEx worker walks past his truck in the North Beach neighborhood on June 23, 2026 in San Francisco, California. Heather Diehl | Getty Images As demand rises for specialized medications like GLP-1s, logistics companies including UPS and FedEx are adapting their strategies to be able to better ship and store those pharmaceuticals. Most injectable…
U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans, on Saturday, April 18, 2026 in the Oval Office at the White House in Washington, D.C. The Washington Post | The Washington Post | Getty Images President Donald Trump said generic drugs imported into the…
